Core Insights - Health Catalyst, Inc. reported strong financial performance for the full year 2024, achieving total revenue of $307 million and Adjusted EBITDA of $26 million, with expectations for continued growth in 2025 [2][4][11] - The Technology segment generated $195 million in revenue for 2024, reflecting a 10% year-over-year growth, and is anticipated to grow faster than the overall business in 2025 [2][4] - The company has made leadership changes, including the appointment of Dr. Jill Hoggard Green to the Board of Directors and promotions within the leadership team [3] Financial Performance - For Q4 2024, total revenue was $79.6 million, a 6% increase from $75.1 million in Q4 2023 [4] - Gross profit for Q4 2024 was $28.6 million, up 20% from $23.9 million in Q4 2023, resulting in a gross margin of 36% [4] - The net loss for Q4 2024 was $20.7 million, a 32% improvement compared to a net loss of $30.3 million in Q4 2023 [4] Key Metrics - The number of Platform Clients increased to 130 in 2024, up from 109 in 2023 [5] - The Dollar-based Retention Rate for the Technology segment and Tech-Enabled Managed Services (TEMS) was 102% [7] - Cash and cash equivalents at the end of 2024 were $249.6 million, significantly higher than $106.3 million at the end of 2023 [17][24] Financial Outlook - For Q1 2025, the company expects total revenue of approximately $79 million and Adjusted EBITDA of approximately $4 million [11] - For the full year 2025, total revenue is projected to be approximately $335 million, with Technology revenue expected to reach approximately $220 million and Adjusted EBITDA targeted at approximately $41 million [11]

Company Overview - Health Catalyst, Inc. is a leading provider of data and analytics technology and services for healthcare organizations [3] - The company offers a cloud-based technology ecosystem called Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services [3] - More than 1,000 organizations globally rely on Health Catalyst's offerings to drive measurable clinical, financial, and operational improvements [3] Upcoming Financial Results - Health Catalyst will release its fourth quarter and full year 2024 operating results on February 26, 2025, after market close [1] - A conference call to review the results will be held at 5:00 pm ET on the same day [1] Conference Call Details - U.S. participants can access the conference call by dialing 800-343-5172, while international participants can call 203-518-9856, referencing conference ID "HCATQ424" [2] - A live audio webcast will be available online, with a replay accessible shortly after the call for approximately 90 days [2]

Core Insights - Health Catalyst, Inc. has announced a multi-year partnership with OrthoNebraska to enhance orthopedic care through data and analytics technology [1][5] - The partnership will utilize Health Catalyst Ignite™, a comprehensive data and analytics ecosystem designed to improve patient outcomes and operational efficiency [2][5] Company Overview - Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,000 clients globally and a focus on measurable clinical, financial, and operational improvements [6] - OrthoNebraska is the largest orthopedic provider in eastern Nebraska and southwestern Iowa, offering a wide range of services including surgical and non-surgical interventions [7] Partnership Details - OrthoNebraska will access Health Catalyst Expert Data Collections™, integrating various clinical, financial, and patient experience data into a unified model for better decision-making [3][4] - The partnership aims to simplify and personalize the healthcare experience by providing near real-time information to specialized teams [4] Operational Support - Health Catalyst will provide ongoing operational support to OrthoNebraska, including data source configuration, governance, and security administration [4][5] - The Ignite platform is designed to be scalable and purpose-built for healthcare, enabling OrthoNebraska to achieve its goals in delivering exceptional patient care [5]

Core Viewpoint - Health Catalyst, Inc. has signed a definitive agreement to acquire Upfront Healthcare Services, Inc., aiming to enhance patient engagement and experience through the integration of Upfront's technology with Health Catalyst's existing offerings [1][6]. Company Overview - Health Catalyst is a leading provider of data and analytics technology and services for healthcare organizations, with over 1,000 clients globally relying on its solutions to drive clinical, financial, and operational improvements [7]. - Upfront Healthcare is a mission-driven company that offers a patient engagement platform, utilizing data analytics to personalize patient outreach and improve care experiences [8][9]. Acquisition Details - The acquisition is expected to close in the first quarter of 2025, with Health Catalyst planning to fund the transaction through a mix of cash and stock [1][6]. - Upfront's platform focuses on patient activation and engagement, providing automated solutions for patient acquisition and retention, which will complement Health Catalyst's existing patient engagement tools [2][3]. Strategic Benefits - The combination of Upfront's expertise in patient acquisition and scheduling with Health Catalyst's robust patient engagement portfolio is anticipated to enhance the overall patient experience [3][4]. - The integration of Upfront's technology with Health Catalyst Ignite™ Data and Analytics aims to provide healthcare clients with improved patient care through data-driven insights [5][6].

Core Insights - Health Catalyst, Inc. has been recognized as a leader in innovation in the Frost Radar™: US Population Health Management, 2024 report, solidifying its position in the competitive population health management market [1][2][3] Company Overview - Health Catalyst provides data and analytics technology and services to healthcare organizations, focusing on enhancing care delivery and outcomes through its Population Health suite, which includes financial and quality benchmarking tools, administrative support, and advanced analytics [2][3] - The company has a multi-decade mission dedicated to equipping healthcare organizations with tools for data-informed healthcare improvement and operational efficiency [3][6] Innovation and Growth - The report highlights Health Catalyst's optimization efforts, including custom configuration, a pre-built rules engine, and superior data management capabilities, which contribute to the success of population health management initiatives [3][4] - Health Catalyst's proactive approach to innovation is underscored by its strategic acquisitions, such as Carevive and Lumeon, which enhance its capabilities in oncology care management and patient communication [3][5] Market Position - Analysts commend Health Catalyst's balanced focus on growth and innovation, which positions the company well to meet the needs of clients of all sizes [4][5] - The company's strategic expansion into underserved segments, including ambulatory practices and smaller healthcare organizations, further solidifies its leadership in the population health management market [5]

Investment Thesis - The company, Health Catalyst (NASDAQ: HCAT), is recommended as a buy due to expected growth acceleration driven by an improved macro environment and traction with the Ignite platform [1] - The investment is considered ideal if the company operates in a sector projected to experience structural (organic) growth exceeding GDP growth over the next 5-10 years [1] - The company should profit from sustainable competitive advantages that translate into attractive unit economics [1] - The company should be managed by competent, ethical, and long-term thinkers [1] - The company should have a fair valuation [1] Analyst's Position - The analyst has no stock, option, or similar derivative position in any of the companies mentioned and no plans to initiate any such positions within the next 72 hours [1] - The article expresses the analyst's own opinions and is not receiving compensation for it (other than from Seeking Alpha) [1] - The analyst has no business relationship with any company whose stock is mentioned in the article [1]

SALT LAKE CITY, Nov. 20, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"  Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of an AI-powered version of BluePrint Protect™ from Intraprise Health, LLC ("Intraprise Health"), a platform that empowers healthcare organizations to screen and identify risks related to cybersecurity threats through third parties.On Nov. 6, Health Catalyst announced it signed a defini ...

SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, Dan LeSueur, Chief Operating Officer, and Jack Knight, Vice President of Investor Relations, will participate in the Stephens Annual Investment Conference, being held in Nashville, including a fireside chat on Wedne ...

Health Catalyst, Inc. (NASDAQ:HCAT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Jack Knight - VP, IR Dan Burton - CEO Dan LeSueur - COO Jason Alger - CFO Conference Call Participants Jared Haase - William Blair Jessica Tassan - Piper Sandler Anna Kruszenski - Barclays Bank John Pinney - Canaccord Genuity Thomas Kelliher - RBC Capital Markets David Larsen - BTIG John Ransom - Raymond James Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Operator Welcome to the ...

Health Catalyst (HCAT) reported $76.35 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 3.5%. EPS of $0.07 for the same period compares to $0.03 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $76.2 million, representing a surprise of +0.20%. The company delivered an EPS surprise of -30.00%, with the consensus EPS estimate being $0.10.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...